14102 studies
BACKGROUND Tirzepatide is effective for glycemic control and weight management in type 2 diabetes and obesity. Clinical trials have demonstrated tirzepatide's lower risk of acute kidney injury (AKI) compared with existing glucagon-like peptide-1 rece…
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have recently garnered increased attention due to their effectiveness in inducing marked weight loss among overweight and obese adults. Recent evidence, however, has raised concerns a…
BACKGROUND: Obesity is a chronic disease with significant global health repercussions. GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists (GIP/GLP-1RAs) are now established as evidence-based options for long-term obesity manageme…
Obesity prevalence is rapidly increasing worldwide, necessitating diverse treatment approaches ranging from pharmacotherapy to surgical interventions. Tirzepatide, a recently approved dual GIP/GLP-1 receptor agonist, has shown therapeutic promise, bu…
BACKGROUND AND HYPOTHESIS: In patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), there remains a paucity of data from large high-quality real-world studies on the efficacy of weight-lowering interventions, including the g…
Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) treat overweight or obesity with or without diabetes. This review aims to evaluate the effects of GLP-1 RAs on weight and cardiometabolic measures. This systematic review and meta-analysis of ra…
Obesity confers substantial cardiometabolic risk. Tirzepatide, a once-weekly dual GIP/GLP-1 receptor agonist, produces dose-dependent weight loss in trials, but real-world patient-reported experiences are under-described. We evaluated real-world self…
BACKGROUND: Cardiovascular diseases, overweight, type 2 diabetes and chronic kidney disease increase the risk of cardiovascular events.Glucagon-like peptide-1 analogues are recommended by the European Society of Cardiology and the American College of…
Tirzepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide receptor agonist, is increasingly prescribed privately in the United Kingdom for weight loss. While gastrointestinal side effects are well recognized, se…
The World Health Organisation (WHO) periodically updates its Model List of Essential Medicines (EML) and Essential Medicines for Children (EMLc) to address evolving global health priorities. The 24th EML and 10th EMLc, released on 5th September 2025,…
The coexistence of type 2 diabetes (T2D), metabolic dysfunction-associated steatotic liver disease (MASLD), and cardiovascular disease (CVD) defines a clinical profile that is frequently observed in clinical practice. In addition to being highly prev…
BACKGROUND: Several societies recommend sodium-glucose co-transporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and finerenone for cardiorenal risk reduction in select populations. This updated meta-analysis assessed…
BACKGROUND: To compare the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) versus bariatric surgery on cardiovascular outcomes in patients with heart failure (HF) with preserved ejection fraction and obesity. METHODS: Using the…
Obstructive sleep apnoea (OSA) is a prevalent disorder marked by recurrent upper airway obstruction during sleep, often linked to obesity and poor continuous positive airway pressure (CPAP) adherence. Tirzepatide, a dual GIP and GLP-1 receptor agonis…
BACKGROUND: Obesity and associated metabolic disorders such as type 2 diabetes mellitus and polycystic ovary syndrome are rising globally, contributing to infertility and adverse pregnancy outcomes. This review synthesizes current evidence on pharmac…
Diabetes and metabolic disorders represent a global health crisis driven by complex interactions between metabolic, immune, and microbial networks. Beyond their metabolic derangements- hyperglycemia, insulin resistance, and low-grade systemic inflamm…
Obstructive sleep apnea (OSA) is a common sleep-related breathing disorder defined by repeated upper airway collapse, intermittent hypoxia, and sleep disruption. Continuous positive airway pressure (CPAP) is the gold-standard treatment of moderate-to…